


LIST OF TABLES

	Page
Table I	14
Table 1.1	23
Table 1.2	26
Table 1.3	27
Table 1.4	27
Table 1.5	27
Table 1.6	28
Table 1.7	28
Table 1.8	29
Table 1.9	30
Table 1.10	30
Table 1.11	30
Table 1.12	31
Table 1.13	32
Table 1.14	33
Table 1.15	34
Table 1.16	35
Table 2.1	41
Table 2.2	42
Table 2.3	42
Table 2.4	43
Table 2.5	43
Table 2.6	44
Table 2.7	45
Table 2.8	46
Table 2.9	46

	Page
Table 2.10	Sensitivity and diagnostic results of breast tissue biopsies (N=16,595) 47
Table 2.11	Method of clinical staging in 7,016 invasive breast cancer patients 48
Table 2.12	Use of PET scan as a form of staging method among patients by cancer stage (N=7,016) 48
Table 2.13	Histological type, grading, multifocality and multicentricity of invasive breast cancers (N=14,234) 51
Table 2.14	Biological characteristics of invasive breast cancers (N=14,234) 52
Table 2.15	Biological subtypes of invasive tumours by cancer stage (N=13,355) 53
Table 2.16	Histological type, grading, multifocality and multicentricity of in situ breast cancers (N=2,194) 54
Table 2.17	Biological characteristics of in situ breast cancers (N=2,194) 54
Table 2.18	Type of surgery (N=16,583) 56
Table 2.19	Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=6,478) 60
Table 2.20	Use of chemotherapy by age group and cancer stage at diagnosis (N=13,242) 61
Table 2.21	Number of treatment modalities received by patients by cancer stage (N=15,654) 68
Table 2.22	Follow-up of 14,699 patients 69
Table 2.23	Locoregional recurrence by type of surgery and cancer stage 70
Table 2.24	Sites involved in locoregional recurrence (N=388) 70
Table 2.25	Organs involved in distant recurrence (N=494) 71
Table 2.26	Locoregional and distant recurrence among invasive breast cancer patients by cancer stage 71
Table 2.27	Characteristics of breast cancer-specific deaths (N=181) 72
Table 3.1	Five most common forms of discomfort after surgery (N=14,681) 75
Table 3.2	Five most common forms of discomfort after radiotherapy (N=8,769) 76
Table 3.3	Five most common forms of discomfort after chemotherapy (N=8,954) 77
Table 3.4	Five most common forms of discomfort after endocrine therapy (N=9,452) 77
Table 3.5	Five most common forms of discomfort after anti-HER2 targeted therapy (N=1,810) 78
Table 3.6	Psychosocial impact of breast cancer 79
Table 3.7	Psychosocial adjustments and coping strategies for survivorship 80



LIST OF FIGURES

	Page
Figure I	10
Figure I	10
Figure II	14
Figure 1.1	23
Figure 1.2	23
Figure 1.3	24
Figure 1.4	24
Figure 1.5	24
Figure 1.6	25
Figure 1.7	25
Figure 1.8	31
Figure 2.1	41
Figure 2.2	42
Figure 2.3	44
Figure 2.4	45
Figure 2.5	46
Figure 2.6	49
Figure 2.7	49
Figure 2.8	50
Figure 2.9	50
Figure 2.10	57
Figure 2.11	57
Figure 2.12	57
Figure 2.13	57
Figure 2.14	58
Figure 2.15	58
Figure 2.16	58
Figure 2.17	59
Figure 2.18	60

	Page
Figure 2.19 Patients who underwent both mastectomy and locoregional radiotherapy by cancer stage (N=9,871)	60
Figure 2.20 Chemotherapy treatment by cancer stage (N=13,732)	61
Figure 2.21 Type of chemotherapy regimens in neoadjuvant setting in patients by biological subtype (N=939)	62
Figure 2.22 Type of chemotherapy regimens in adjuvant setting in patients by biological subtype (N=7,172)	63
Figure 2.23 Type of chemotherapy regimens in adjuvant setting in patients by cancer stage (N=7,314)	64
Figure 2.24 Type of chemotherapy regimens in palliative setting in patients by biological subtype (N=289)	65
Figure 2.25 Endocrine therapy rates by cancer stage (N=15,829)	66
Figure 2.26 Forms of endocrine therapy by age group (N=10,095)	66
Figure 2.27 Anti-HER2 targeted therapy rate in HER2 positive patients by cancer stage (N=2,944)	67
Figure 2.28 Type of complementary and alternative therapies used in 6,378 patients	68
Figure 3.1 Level of physical discomfort after surgery (N=14,681)	75
Figure 3.2 Level of physical discomfort by type of surgery (N=14,646)	75
Figure 3.3 Level of physical discomfort after radiotherapy (N=8,769)	76
Figure 3.4 Level of physical discomfort after radiotherapy by irradiated regions (N=5,998)	76
Figure 3.5 Level of physical discomfort after chemotherapy (N=8,954)	76
Figure 3.6 Level of physical discomfort after endocrine therapy (N=9,452)	77
Figure 3.7 Level of physical discomfort after anti-HER2 targeted therapy (N=1,810)	77
Figure 3.8 Level of physical discomfort after complementary and alternative therapies (N=6,378)	78
Figure 3.9 Change in outlook on life by age group (N=14,114)	79
Figure 3.10 Change in self-image by age group (N=14,114)	80
Figure 3.11 Level of worry about recurrence by age group (N=14,150)	80